- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.04. | Serif, Flagship's latest biotech, aims to make a new kind of genetic medicine | ||
| 20.04. | RFK Jr. defends HHS tenure, 12% proposed budget cut | ||
| 20.04. | Nektar surges again as alopecia drug shows new promise in extension study | ||
| 20.04. | Lilly boosts 'in vivo' cell therapy capabilities with Kelonia buyout | ||
| 20.04. | AACR 2026: Revolution's next prospect, Merck's reveal and a lung cancer battle | ||
| 20.04. | [Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services | ||
| 20.04. | What actually drives speed in complex drug development programs | ||
| 17.04. | UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B | ||
| 17.04. | Lilly's obesity pill off to a strong start; OpenAI debuts new drug discovery tool | ||
| 17.04. | 5 notable pharma CEO pay hikes in 2025 | ||
| 17.04. | Kailera nets $625M in one of biotech's biggest-ever IPOs | ||
| 17.04. | Erica Schwartz, ex-deputy surgeon general, picked to be next CDC director | ||
| 16.04. | FDA moves toward easing restrictions on certain peptides | ||
| 16.04. | Lilly's new obesity pill passes heart safety test in diabetes | ||
| 16.04. | Replimune cuts staff; MeiraGTx reacquires eye gene therapy | ||
| 16.04. | Roche to start new Elevidys study following setback in Europe | ||
| 15.04. | Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers | ||
| 15.04. | Terremoto raises $108M to pursue development of drugs targeting AKT | ||
| 15.04. | FDA asks Lilly to evaluate obesity pill's liver risk | ||
| 15.04. | Obsidian, Galera Therapeutics to advance cell therapy following reverse merger | ||
| 14.04. | Travere wins long-awaited approval for kidney disease drug | ||
| 14.04. | J&J leans on Tremfya, cancer drugs to overcome Stelara losses | ||
| 14.04. | Novo teams with OpenAI; Ideaya gets muted response to eye drug data | ||
| 14.04. | Lilly boosts ADC portfolio with CrossBridge Bio deal | ||
| 13.04. | Spyre drug for inflammatory bowel disease shows promise in early study |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.